Livzon Pharmaceutical Group (HK:1513) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Livzon Pharmaceutical Group has entered into a Patent and Technology Transfer Agreement with South China Vaccine Co. for the development of an influenza recombinant protein vaccine. The agreement involves transferring project rights and technology to Livzon MAB, a subsidiary of Livzon Pharmaceutical, in exchange for fees and royalties. This move positions Livzon MAB to advance in the clinical trials approved by the National Medical Products Administration.
For further insights into HK:1513 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “More Hopeful than Real”: Is a Bidding War Brewing for Warner Bros. Discovery Stock (NASDAQ:WBD)?
- “Didn’t Develop the Way Automakers Thought.” Ford Notches Up, Reconsidering the EV Market
- “Our Focus is Increasingly…on Inference”: Intel Stock (NASDAQ:INTC) Jumps With Crescent Island Testing Next Year